Biogen Asks FDA To Approve Aducanumab
New drug application is first for Alzheimer’s disease in the U.S. since 2003, and first based on amyloid hypothesis.
ALL NEWS
207 RESULTS
Sort By:
- Most Recent
- Most Commented
Seeing into the Human Synapse: New Tools Illuminate Alzheimer’s Hot Spot
New synaptic profiling and imaging techniques are enabling scientists to zero in on synaptic proteins, including phospho-tau, that make the difference between clinical Alzheimer’s and resilience.
You Are What You Breathe: Polluted Air Tied to Plaques, Brain Atrophy
Two cohorts—IDEAS and WHIMS—show Aβ accumulation and brain shrinkage in cognitively normal and impaired elderly who were exposed to levels of air pollution even within current EPA limits.
MTBR-243 Tau: A Fluid Biomarker for Tangles Themselves?
Researchers found that bits of tau from the protein’s microtubule-binding region can be detected in the cerebrospinal fluid. These, not phospho-tau or total tau, reflect neurofibrillary tangles in the Alzheimer’s brain.
Begone 2020: Despite COVID, Alzheimer’s Research Advanced
Confronting unprecedented challenges this past year, scientists found ways to tide their research over and keep clinical trials mostly on track.
Do Lysosomes Help Propagate Tau Seeds?
In cultured cells, lysosomal activity was necessary to enable tau seeds to break out of internalized exosomes and trigger the aggregation of tau in the cytosol.
Positive Phase 2 Results Claimed for Masitinib in Alzheimer’s
Topline results suggested that the anti-inflammatory treatment stabilized cognition and function over six months. The trial did not include biomarkers.
Doubling Down on Sequencing Serves up More Alzheimer’s Genes
New genetic variants emerged by harmonizing whole-exome-sequencing data across continents, and by using imputation to plumb the depths of existing GWAS. One variant encodes a microglial phospholipid transporter.
New Assay, New Cohorts—Plasma p-Tau181 Looks Even Better
At AAT-ADPD, researchers report how they built on prior reports that a person’s blood level of p-tau181 tells if they have Alzheimer’s.
α-Synuclein Antibody Misses Primary, May Have Signal on Secondaries
The first topline Phase 2 results from an antibody targeting Parkinson’s pathology, Roche’s prasinezumab, were a mixed bag. Next steps are unclear.
Umibecestat-Driven Cognitive Decline Is Reversible
Subtle memory deficits resolved after volunteers stopped taking the Novartis BACE inhibitor.
RBFOX1 Gene Tied to Amyloidosis in Preclinical Alzheimer’s
Researchers used PET scans from 4,000 people to link RBFOX1 risk variants to amyloidosis. People with lower RBFOX1 expression in their brains had more amyloid and worse cognition.
Current Filters
- Date Range : Jan 2020 to Jan 2021 x